Evaluation of clinical and immunological effects of PD-1 inhibition on actinic keratoses in patients with advanced or metastatic cutaneous squamous cell carcinoma in combination with a pronounced field cancerization An open label, prospective, observational biomarker study of the DeCOG
Latest Information Update: 21 Mar 2024
At a glance
- Drugs Cemiplimab (Primary)
- Indications Carcinoma; Squamous cell cancer
- Focus Pharmacodynamics
- Acronyms Field Cancerization
Most Recent Events
- 25 Feb 2022 New trial record